Dosing Options

For the treatment of nasal polyps in patients 18 years of age or older

XHANCE is administered in each nostril twice daily.

The recommended dosage is 1 spray per nostril twice daily.

30 days of treatment at this dosage requires 1 unit of XHANCE

XHANCE is also approved for 2 sprays per nostril twice daily.

30 days of treatment at this dosage requires 2 units of XHANCE

XHANCE is fragrance and alcohol free.

Please see Important Safety Information on reverse and accompanying full Prescribing Information and Instructions for Use in pocket.
**Dosing Options**

XHANCE is administered in each nostril twice daily for the treatment of nasal polyps in patients 18 years of age or older. The recommended dosage is:

- For the treatment of nasal polyps in patients 18 years of age or older:
  - 1 spray per nostril twice daily for 30 days of treatment at this dosage requires 1 unit of XHANCE.
  - 2 sprays per nostril twice daily for 30 days of treatment at this dosage requires 2 units of XHANCE.

**ADVERSE REACTIONS:**

The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal ulcers, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

**DRUG INTERACTIONS:**

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

**INDICATION AND USAGE:**

XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

**CONTRAINDICATIONS:**

Hypersensitivity to any ingredient in XHANCE.

**WARNINGS AND PRECAUTIONS:**

- Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.
- Close monitoring for glaucoma and cataracts is warranted.
- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
- Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simples). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
- Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
- Assess for decrease in bone mineral density initially and periodically thereafter.

**IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS:**

Hypersensitivity to any ingredient in XHANCE.

**WARNINGS AND PRECAUTIONS:**

- Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.
- Close monitoring for glaucoma and cataracts is warranted.
- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
- Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simples). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
- Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
- Assess for decrease in bone mineral density initially and periodically thereafter.

**ADVERSE REACTIONS:**

The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal ulcers, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

**DRUG INTERACTIONS:**

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

**USE IN SPECIFIC POPULATIONS:**

Hepatic impairment. Monitor patients for signs of increased drug exposure.

**INDICATION AND USAGE:**

XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.